Research Analysts Set Expectations for ACRS FY2025 Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Aclaris Therapeutics in a research report issued to clients and investors on Tuesday, March 4th. Cantor Fitzgerald analyst P. Agrawal expects that the biotechnology company will post earnings per share of ($0.54) for the year. Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.82) per share.

A number of other research analysts have also issued reports on ACRS. StockNews.com lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 8th. HC Wainwright raised Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Monday, December 23rd. BTIG Research raised shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 target price for the company in a research note on Tuesday, November 19th. Piper Sandler raised Aclaris Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $3.00 to $13.00 in a research note on Monday, November 18th. Finally, Leerink Partners raised shares of Aclaris Therapeutics from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $2.00 to $7.00 in a research report on Tuesday, November 19th. One analyst has rated the stock with a sell rating, five have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $11.00.

Aclaris Therapeutics Trading Down 4.1 %

Shares of ACRS stock opened at $1.85 on Thursday. The firm has a market capitalization of $132.15 million, a price-to-earnings ratio of -3.56 and a beta of 0.50. The business’s 50-day moving average price is $2.38 and its 200-day moving average price is $2.18. Aclaris Therapeutics has a 12 month low of $0.95 and a 12 month high of $5.17.

Hedge Funds Weigh In On Aclaris Therapeutics

Several large investors have recently added to or reduced their stakes in ACRS. ExodusPoint Capital Management LP bought a new position in shares of Aclaris Therapeutics in the fourth quarter valued at approximately $26,000. Invesco Ltd. purchased a new stake in Aclaris Therapeutics in the 4th quarter valued at $28,000. Graham Capital Management L.P. bought a new position in Aclaris Therapeutics during the 4th quarter valued at $35,000. Commonwealth Equity Services LLC purchased a new stake in Aclaris Therapeutics in the 4th quarter valued at about $36,000. Finally, Alpine Global Management LLC purchased a new stake in Aclaris Therapeutics in the 4th quarter valued at about $38,000. Institutional investors own 98.34% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.